Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements

Clinical Pharmacology and Therapeutics

Volumn 79, Issue 4, 2006, Pages 291-302

  Aquilante, Christina L ^a   Langaee, Taimour Y ^a   Lopez, Larry M ^a   Yarandi, Hossein N ^a   Tromberg, Jennifer S ^a   Mohuczy, Dagmara ^a   Gaston, Katherine L ^a   Waddell, Cassandra D ^a   Chirico, Mark J ^a   Johnson, Julie A ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; CARBAMAZEPINE; CYCLOSPORIN; CYTOCHROME P450 2C9; CYTOCHROME P450 INHIBITOR; DILTIAZEM; DNA; GEMFIBROZIL; GENE PRODUCT; GRISEOFULVIN; IMATINIB; KETOCONAZOLE; PHENYTOIN; PRIMIDONE; PROTHROMBIN; SULFAMETHOXAZOLE; UNCLASSIFIED DRUG; VERAPAMIL; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; VITAMIN K GROUP; WARFARIN;

ADULT; AGED; AGING; ALLELE; ARTICLE; BODY WEIGHT; CALCULATION; CONTROLLED STUDY; DNA POLYMORPHISM; DOSE CALCULATION; DRUG TARGETING; ENZYME INDUCTION; FEMALE; GENE DELETION; GENE FUNCTION; GENE INSERTION; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HUMAN; HUMAN CELL; INTERNATIONAL NORMALIZED RATIO; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PRIORITY JOURNAL; SAMPLING; SMOKING; STATISTICAL ANALYSIS; VITAMIN INTAKE;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; BLOOD COAGULATION FACTORS; DNA PRIMERS; FACTOR VII; FACTOR X; FEMALE; GENOTYPE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROTHROMBIN; WARFARIN;

EID: 33645849823     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.11.011     Document Type: Article

References (40)

1. Hirsh J., Dalen J., Anderson D.R., Poller L., Bussey H., Ansell J., et al. Oral anticoagulants. mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119 (2001) 8S-21S
2. Takahashi H., and Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 40 (2001) 587-603
3. Lee C.R., Goldstein J.A., and Pieper J.A. Cytochrome P450 2C9 polymorphisms. a comprehensive review of the in-vitro and human data. Pharmacogenetics 12 (2002) 251-263
4. Takahashi H., Kashima T., Nomoto S., Iwade K., Tainaka H., Shimizu T., et al. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin. catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics 8 (1998) 365-373
5. Rettie A.E., Wienkers L.C., Gonzalez F.J., Trager W.F., and Korzekwa K.R. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4 (1994) 39-42
6. Furuya H., Fernandez-Salguero P., Gregory W., Taber H., Steward A., Gonzalez F.J., et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 5 (1995) 389-392
7. Aithal G.P., Day C.P., Kesteven P.J., and Daly A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353 (1999) 717-719
8. Higashi M.K., Veenstra D.L., Kondo L.M., Wittkowsky A.K., Srinouanprachanh S.L., Farin F.M., et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287 (2002) 1690-1698
9. Gage B.F., Eby C., Milligan P.E., Banet G.A., Duncan J.R., and McLeod H.L. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 91 (2004) 87-94
10. Endler G., and Mannhalter C. Polymorphisms in coagulation factor genes and their impact on arterial and venous thrombosis. Clin Chim Acta 330 (2003) 31-55
11. Green F., Kelleher C., Wilkes H., Temple A., Meade T., and Humphries S. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Thromb 11 (1991) 540-546
12. Bernardi F., Marchetti G., Pinotti M., Arcieri P., Baroncini C., Papacchini M., et al. Factor VII gene polymorphisms contribute about one third of the factor VII level variation in plasma. Arterioscler Thromb Vasc Biol 16 (1996) 72-76
13. Millar D.S., Elliston L., Deex P., Krawczak M., Wacey A.I., Reynaud J., et al. Molecular analysis of the genotype-phenotype relationship in factor X deficiency. Hum Genet 106 (2000) 249-257
14. de Visser M.C., Poort S.R., Vos H.L., Rosendaal F.R., and Bertina R.M. Factor X levels, polymorphisms in the promoter region of factor X, and the risk of venous thrombosis. Thromb Haemost 85 (2001) 1011-1017
15. Oldenburg J., Quenzel E.M., Harbrecht U., Fregin A., Kress W., Muller C.R., et al. Missense mutations at ALA-10 in the factor IX propeptide. an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy. Br J Haematol 98 (1997) 240-244
16. Li T., Chang C.Y., Jin D.Y., Lin P.J., Khvorova A., and Stafford D.W. Identification of the gene for vitamin K epoxide reductase. Nature 427 (2004) 541-544
17. Rost S., Fregin A., Ivaskevicius V., Conzelmann E., Hortnagel K., Pelz H.J., et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427 (2004) 537-541
18. Rieder M.J., Reiner A.P., Gage B.F., Nickerson D.A., Eby C.S., McLeod H.L., et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352 (2005) 2285-2293
19. D'Andrea G., D'Ambrosio R.L., Di Perna P., Chetta M., Santacroce R., Brancaccio V., et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105 (2005) 645-649
20. Yuan H.Y., Chen J.J., Lee M.T., Wung J.C., Chen Y.F., Charng M.J., et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 14 (2005) 1745-1751
21. Wadelius M., Chen L.Y., Downes K., Ghori J., Hunt S., Eriksson N., et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmaco-genomics J 5 (2005) 262-270
22. Sconce E.A., Khan T.I., Wynne H.A., Avery P., Monkhouse L., King B.P., et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements. proposal for a new dosing regimen. Blood 106 (2005) 2329-2333
23. Gage B.F., Fihn S.D., and White R.H. Management and dosing of warfarin therapy. Am J Med 109 (2000) 481-488
24. 1 (phylloquinone) content of foods. a provisional table. J Food Compost Anal 6 (1993) 100-20
25. Booth S.L., and Centurelli M.A. Vitamin K. a practical guide to the dietary management of patients on warfarin. Nutr Rev 57 (1999) 288-296
26. Langaee T., and Ronaghi M. Genetic variation analyses by Pyrosequencing. Mutat Res 573 (2005) 96-102
27. Andrisin T.E., Humma L.M., and Johnson J.A. Collection of genomic DNA by the noninvasive mouthwash method for use in pharmacogenetic studies. Pharmacotherapy 22 (2002) 954-960
28. Aquilante C.L., Lobmeyer M.T., Langaee T.Y., and Johnson J.A. Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory. Pharmacotherapy 24 (2004) 720-726
29. Dell'Acqua G., Iacoviello L., D'Orazio A., Di Bitondo R., Di Castelnuovo A., and Donati M.B. A polymorphic cluster in the 5' region of the human coagulation factor VII gene. detection, frequency, and linkage disequilibrium. Thromb Res 88 (1997) 445-448
30. Hansten P.D., and Horn J.R. The top 100 drug interactions. a guide to patient management (2003), H&H Publications, Edmonds (WA)
31. Daly A.K., and Aithal G.P. Genetic regulation of warfarin metabolism and response. Semin Vasc Med 3 (2003) 231-238
32. Loebstein R., Yonath H., Peleg D., Almog S., Rotenberg M., Lubetsky A., et al. Interindividual variability in sensitivity to warfarin-nature or nurture?. Clin Pharmacol Ther 70 (2001) 159-164
33. James A.H., Britt R.P., Raskino C.L., and Thompson S.G. Factors affecting the maintenance dose of warfarin. J Clin Pathol 45 (1992) 704-706
34. Yarandi H.N. Using the SAS system to estimate sample size and power for comparing two binomial proportions. Nurs Res 43 (1994) 124-125
35. Girelli D., Russo C., Ferraresi P., Olivieri O., Pinotti M., Friso S., et al. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. N Engl J Med 343 (2000) 774-780
36. D'Ambrosio R.L., D'Andrea G., Cappucci F., Chetta M., Di Perna P., Brancaccio V., et al. Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin. Haematologica 89 (2004) 1510-1516
37. Taube J., Halsall D., and Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96 (2000) 1816-1819
38. Margaglione M., Colaizzo D., D'Andrea G., Brancaccio V., Ciampa A., Grandone E., et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 84 (2000) 775-778
39. Joffe H.V., Xu R., Johnson F.B., Longtine J., Kucher N., and Goldhaber S.Z. Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost 91 (2004) 1123-1128
40. National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health. Single nucleotide polymorphism. Available from: URL:http://www.ncbi.nlm.nih.gov/SNP/. Accessed Feb 7, 2006.